Literature DB >> 1345786

Yersinia enterocolitica produces superantigenic activity.

P M Stuart1, J G Woodward.   

Abstract

We have recently observed that antigenic preparations from Yersinia enterocolitica are capable of inducing strong proliferative responses in normal murine spleen cell cultures. As a consequence of this observation, we evaluated whether Yersinia-derived Ag possess superantigenic activity. Stimulatory activity can be found in culture supernatants, as well as membrane and cytoplasmic fractions of Y. enterocolitica. Cell depletion studies indicate that the primary responding cell is a CD4+ T cell, which requires the presence of APC for responsiveness to Y. enterocolitica Ag. Furthermore, these APC must express MHC class II Ag, as evidenced by the fact that either antibody depletion of class II+ APC or addition of anti-class II antibodies (that block class II Ag on the surface of APC) eliminates the proliferative response. Evaluation of TCR usage by BALB/c T cells responsive to Y. enterocolitica revealed that those T cells bearing V beta 3, 6, and 11 and possibly 7 and 9 were expanded after exposure to Y. enterocolitica Ag preparations. By using a panel of T cell hybridomas, we have shown that hybridomas bearing V beta 3, 7, 8.1, 9, and 11 but not 2, 8.2, 8.3, and 13 respond to Yersinia. When cytoplasmic fractions of Y. enterocolitica were subjected to column chromatography, proliferative activity was enriched approximately 27-fold, and the elution characteristics of the active material suggest that it possesses hydrophobic regions and is, therefore, probably membrane associated. These data indicate that Y. enterocolitica produces antigenic material that has properties consistent with those of T cell superantigens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1345786

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations.

Authors:  Inés Colmegna; Raquel Cuchacovich; Luis R Espinoza
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 2.  Potential role of superantigen induced activation of cell mediated immune mechanisms in the pathogenesis of Crohn's disease.

Authors:  J P Ibbotson; J R Lowes
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

Review 3.  Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis.

Authors:  B Henderson; S Poole; M Wilson
Journal:  Microbiol Rev       Date:  1996-06

Review 4.  Superantigens in insulin-dependent diabetes mellitus.

Authors:  P Luppi; M Trucco
Journal:  Springer Semin Immunopathol       Date:  1996

Review 5.  Superantigens related to B cell hyperplasia.

Authors:  N M Ponzio; V K Tsiagbe; G J Thorbecke
Journal:  Springer Semin Immunopathol       Date:  1996

6.  Reactive arthritis-associated bacteria can stimulate lymphocyte proliferation in non-exposed individuals and newborns.

Authors:  F Chieco-Bianchi; K Hedley; T Weissensteiner; G S Panayi; G H Kingsley
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

Review 7.  Bacterial and viral superantigens: roles in autoimmunity?

Authors:  H Acha-Orbea
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

8.  Differential induction of tumor necrosis factor alpha in murine and human leukocytes by Mycoplasma arthritidis-derived superantigen.

Authors:  L Rink; W Nicklas; L Alvarez-Ossorio; M Koester; H Kirchner
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

9.  The superantigen gene ypm is located in an unstable chromosomal locus of Yersinia pseudotuberculosis.

Authors:  Christophe Carnoy; Stephanie Floquet; Michael Marceau; Florent Sebbane; Stephanie Haentjens-Herwegh; Annie Devalckenaere; Michel Simonet
Journal:  J Bacteriol       Date:  2002-08       Impact factor: 3.490

10.  Purification and partial characterization of a product from Yersinia pseudotuberculosis with the ability to activate human T cells.

Authors:  T Miyoshi-Akiyama; K Imanishi; T Uchiyama
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.